UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b)of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Item 5.07 Submission of Matters to a Vote of Security Holders
On June 4, 2024, TFF Pharmaceuticals, Inc. held its 2024 Annual Meeting of Stockholders, for the purposes of:
| ● | Electing seven (7) directors, each to serve until our 2025 Annual Meeting of Stockholders; | |
| ● | Approving an amendment to our 2021 Stock Incentive Plan to increase the number of shares reserved under the plan; and | |
| ● | Ratifying the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. |
All of the persons nominated to serve on our board of directors, namely Harlan Weisman, M.D., Brandi Roberts, Robert S. Mills, Stephen C. Rocamboli, Catherine Lee, Michael Patane, Ph.D. and Thomas B. King, were elected to our board of directors, with shares voted as follows:
| Name | For | Withheld | Broker Non-Votes | |||||||||
| Harlan Weisman | 983,540 | 23,309 | 448,361 | |||||||||
| Brandi Roberts | 969,004 | 37,845 | 448,361 | |||||||||
| Robert S. Mills | 892,721 | 114,128 | 448,361 | |||||||||
| Stephen C. Rocamboli | 891,799 | 115,050 | 448,361 | |||||||||
| Catherine Lee | 970,401 | 36,448 | 448,361 | |||||||||
| Michael Patane, Ph.D. | 961,243 | 45,606 | 448,361 | |||||||||
| Thomas B. King | 963,896 | 42,953 | 448,361 | |||||||||
In addition, our shareholders approved an amendment to our 2021 Stock Incentive Plan, with shares voted as follows:
| For | 821,962 | |||
| Against | 168,284 | |||
| Abstain | 16,603 |
There were 448,361 broker non-votes on the approval the amendment to our 2021 Stock Incentive Plan.
In addition, our shareholders ratified the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024, with shares voted as follows:
| For | 1,430,941 | |||
| Against | 17,616 | |||
| Abstain | 6,653 |
There were no broker non-votes on the ratification of our independent registered public accounting firm.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
TFF PHARMACEUTICALS, INC. |
| Dated: June 7, 2024 | /s/ Kirk Coleman |
| Kirk Coleman, | |
| Chief Financial Officer |
2
Cover |
Jun. 04, 2024 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Jun. 04, 2024 |
| Entity File Number | 001-39102 |
| Entity Registrant Name | TFF PHARMACEUTICALS, INC. |
| Entity Central Index Key | 0001733413 |
| Entity Tax Identification Number | 82-4344737 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 1751 River Run |
| Entity Address, Address Line Two | Suite 400 |
| Entity Address, City or Town | Fort Worth |
| Entity Address, State or Province | TX |
| Entity Address, Postal Zip Code | 76107 |
| City Area Code | (817) |
| Local Phone Number | 438-6168 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common stock: Par value $.001 |
| Trading Symbol | TFFP |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | false |